| Patent Number |
Title Of Patent |
Date Issued |
| 7435412 |
Chronic lymphocytic leukemia cell line |
October 14, 2008 |
| The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are useful in studying and |
| 7427665 |
Chronic lymphocytic leukemia cell line |
September 23, 2008 |
| A CLL line, CLL-AAT, and the preparation and characterization of antibodies using said cell line is disclosed. |
| 7414111 |
Engineered templates and their use in single primer amplification |
August 19, 2008 |
| Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynuc |
| 7408041 |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
August 5, 2008 |
| Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular c |
| 7405279 |
Chimeric proteins for diagnosis and treatment of diabetes |
July 29, 2008 |
| Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are |
| 7399594 |
Hybrid antibodies |
July 15, 2008 |
| Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibo |
| 7396917 |
Rationally designed antibodies |
July 8, 2008 |
| Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities. |
| 7393648 |
Hybrid antibodies |
July 1, 2008 |
| Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibo |
| 7384915 |
Chimeric insulin-gad proteins for treating patients with type 1 diabetes or at risk of developin |
June 10, 2008 |
| Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are |
| 7361339 |
Methods for reducing morality associated with acute myocardial infarction |
April 22, 2008 |
| Methods of reducing mortality in myocardial infarction patients receiving a stent in connection with percutaneous transluminal coronary angioplasty include administering an anti-inflammatory compound to the patient. In one embodiment, the anti-inflammatory compound is an antibody to a |
| 7306906 |
Engineered templates and their use in single primer amplification |
December 11, 2007 |
| Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynuc |
| 7279158 |
Methods for the treatment of inflammatory joint disease |
October 9, 2007 |
| The use of compounds that block complement component C5 or its active fragments C5a and/or C5b (such compounds collectively referred to as "C5 blockers") to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 blockers has been found to: 1) arrest |
| 6982323 |
Chimeric proteins for diagnosis and treatment of diabetes |
January 3, 2006 |
| Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are |
| 6919189 |
Nested oligonucleotides containing a hairpin for nucleic acid amplification |
July 19, 2005 |
| Templates that are engineered to contain a predetermined sequence and a hairpin structure are provided by a nested oligonucleotide extension reaction. The engineered template allows Single Primer Amplification (SPA) to amplify a target sequence within the engineered template. In part |
| 6803230 |
Phagemid vectors |
October 12, 2004 |
| Phagemid vectors containing a sequence of features between a Col E1 origin and an f1 origin are useful for display of polypeptides or proteins, including antibody libraries. |
| 6498285 |
Methods for producing transgenic pigs by microinjecting a blastomere |
December 24, 2002 |
| A transgenic large mammal is produced by a method including the steps of obtaining one or more early embryos, selectively preparing an embryo having at least three cells, and preferably at a stage in development corresponding in time to the onset of transcription of the embryo's pate |
| 6355245 |
C5-specific antibodies for the treatment of inflammatory diseases |
March 12, 2002 |
| The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated |
| 6338820 |
Apparatus for performing assays at reaction sites |
January 15, 2002 |
| An apparatus for performing a assays includes an axially rotatable substrate including a plurality of layers of a semiconductor material and numerous radially-arrayed reaction sites. The apparatus further includes a rotary stepper motor which rotates the substrate at an adjustable and |
| 6074642 |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephri |
June 13, 2000 |
| The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated |
| 6040428 |
Porcine E-selectin |
March 21, 2000 |
| A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as |
| 5891645 |
Porcine E-selectin |
April 6, 1999 |
| A porcine E-selectin protein, its amino acid sequence, the sequence of a cDNA encoding the protein, antibodies reactive with the protein, and methods for the use of these molecules are disclosed. The molecules are used to diagnose the rejection of xenotransplanted pig organs, as well as |
| 5871997 |
Methods and compositions for protecting retroviral vector particles and producer cells from inac |
February 16, 1999 |
| Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The reduction of levels of galactose alpha (1,3) galactosyl epitopes on the |
| 5853722 |
Use of C5-specific antibodies for reducing immune and hemostatic dysfunctions during extracorpor |
December 29, 1998 |
| The use of anti-C5 antibodies to reduce the dysfunction of the immune and hemostatic systems associated with extracorporeal circulation procedures, such as, cardiopulmonary bypass procedures, is disclosed. The antibodies have been found to significantly reduce complement activation, plat |
| 5847082 |
Terminal complement inhibitor fusion proteins |
December 8, 1998 |
| Nucleic acid sequences encoding chimeric proteins that comprise a functional portion of a parent terminal complement inhibitor, such as CD59, and a heterologous transmembrane domain are provided. The parent terminal complement inhibitor is modified to inactivate its GPI signal sequen |
| 5643770 |
Retroviral vector particles expressing complement inhibitor activity |
July 1, 1997 |
| Modified retroviral vector particles and modified retroviral producer cells producing such particles are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The |
| 5627264 |
Chimeric complement inhibitor proteins |
May 6, 1997 |
| Chimeric complement inhibitor proteins are provided which include a first functional domain (first amino acid sequence) having C3 inhibitory activity and a second functional domain (second amino acid sequence) having C5b-9 inhibitory activity. The first functional domain is amino ter |
| 5624837 |
Nucleic acid encoding chimeric complement inhibitor proteins |
April 29, 1997 |
| Chimeric complement inhibitor proteins are provided which include a first functional domain (first amino acid sequence) having C3 inhibitory activity and a second functional domain (second amino acid sequence) having C5b-9 inhibitory activity. The first functional domain is amino ter |
| 5580766 |
Retroviral vector particles for transducing non-proliferating cells |
December 3, 1996 |
| Retroviral vector particles are provided which contain: 1) oncoretroviral gag, pol, and env proteins, including an oncoretroviral gag capsid protein which has been mutated so as to contain a nuclear localization signal (NLS) sequence; and 2) at least one exogenous gene. The particles can |
| 5576201 |
Retroviral vector particles for transducing non-proliferating cells |
November 19, 1996 |
| Retroviral vector particles are provided which contain: 1) oncoretroviral gag, pol, and env proteins, including an oncoretroviral gag matrix protein which has been mutated so as to contain a nuclear localization signal (NLS) sequence; and 2) at least one exogenous gene. The particles can |
| 5562904 |
Retroviral transduction of cells using soluble complement inhibitors |
October 8, 1996 |
| Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The administration of soluble complement inhibitor molecules to body fluids |
